PL2831117T3 - Przeciwciała anty-TLR4 i ich zastosowania - Google Patents
Przeciwciała anty-TLR4 i ich zastosowaniaInfo
- Publication number
- PL2831117T3 PL2831117T3 PL13715871T PL13715871T PL2831117T3 PL 2831117 T3 PL2831117 T3 PL 2831117T3 PL 13715871 T PL13715871 T PL 13715871T PL 13715871 T PL13715871 T PL 13715871T PL 2831117 T3 PL2831117 T3 PL 2831117T3
- Authority
- PL
- Poland
- Prior art keywords
- tlr4 antibodies
- tlr4
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261617164P | 2012-03-29 | 2012-03-29 | |
EP13715871.3A EP2831117B1 (en) | 2012-03-29 | 2013-03-29 | Anti-tlr4 antibodies and uses thereof |
PCT/US2013/034543 WO2013149111A2 (en) | 2012-03-29 | 2013-03-29 | Anti-tlr4 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2831117T3 true PL2831117T3 (pl) | 2018-03-30 |
Family
ID=48087767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL13715871T PL2831117T3 (pl) | 2012-03-29 | 2013-03-29 | Przeciwciała anty-TLR4 i ich zastosowania |
Country Status (11)
Country | Link |
---|---|
US (4) | US9453076B2 (pl) |
EP (1) | EP2831117B1 (pl) |
JP (2) | JP6419064B2 (pl) |
CN (2) | CN107868128A (pl) |
AU (1) | AU2013237929B2 (pl) |
CA (1) | CA2869048C (pl) |
DK (1) | DK2831117T3 (pl) |
ES (1) | ES2651692T3 (pl) |
HU (1) | HUE037613T2 (pl) |
PL (1) | PL2831117T3 (pl) |
WO (1) | WO2013149111A2 (pl) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3056568T3 (da) | 2006-03-31 | 2021-11-01 | Chugai Pharmaceutical Co Ltd | Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik |
SI2173381T1 (sl) * | 2007-05-14 | 2014-01-31 | Novimmune Sa | Fc receptor-vezavni polipeptidi z modificiranimi efektorskimi funkcijami |
JP5334319B2 (ja) | 2007-09-26 | 2013-11-06 | 中外製薬株式会社 | Cdrのアミノ酸置換により抗体の等電点を改変する方法 |
CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
SG10201509790YA (en) | 2010-11-30 | 2015-12-30 | Chugai Pharmaceutical Co Ltd | Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly |
HUE037613T2 (hu) | 2012-03-29 | 2018-09-28 | Novimmune Sa | Anti-TLR4 antitestek és azok felhasználása |
AU2014359077A1 (en) | 2013-12-06 | 2016-07-21 | Novimmune S.A. | Anti-TLR4 antibodies and methods of use thereof |
RU2016134913A (ru) | 2014-02-28 | 2018-03-30 | Астеллас Фарма Инк. | Новое биспецифическое антитело, связывающееся с tlr2 человека и tlr4 человека |
CN104013979B (zh) * | 2014-05-28 | 2016-06-15 | 上海纳米技术及应用国家工程研究中心有限公司 | 肠道靶向造影剂的制备方法 |
PT3233921T (pt) | 2014-12-19 | 2021-12-09 | Chugai Pharmaceutical Co Ltd | Anticorpos anti-c5 e processos para a sua utilização |
CN105949319A (zh) * | 2016-04-27 | 2016-09-21 | 柳州市工人医院 | 作为TLR4信号通路抑制剂用于结肠癌治疗的sTLR4和MD2蛋白复合物 |
SG11201801024XA (en) | 2016-08-05 | 2018-05-30 | Chugai Pharmaceutical Co Ltd | Therapeutic or preventive compositions for il-8-related diseases |
EP3864048A1 (en) | 2018-10-11 | 2021-08-18 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Bacteria expressing single chain antibodies against toll-like receptors |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0279862B1 (en) | 1986-08-28 | 1993-11-03 | Teijin Limited | Cytocidal antibody complex and process for its preparation |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
DK0479909T3 (da) | 1989-06-29 | 1997-04-07 | Medarex Inc | Bispecifikke reagenser til AIDS-behandling |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Hiv感染治療のための異種複合抗体 |
EP0666923A1 (en) | 1991-09-05 | 1995-08-16 | The University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
ATE381614T1 (de) | 1992-07-24 | 2008-01-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
AU1925195A (en) | 1994-02-22 | 1995-09-04 | Dana-Farber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
EP1709970A1 (en) | 1995-04-27 | 2006-10-11 | Abgenix, Inc. | Human antibodies against EGFR, derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
US6399857B1 (en) * | 1999-09-22 | 2002-06-04 | Paradigm Genetics, Inc. | Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species |
CA2548990C (en) * | 2003-12-10 | 2014-09-23 | Novimmune Sa | Toll-like receptor 4 (tlr4)-neutralizing antibodies |
US7674884B2 (en) | 2003-12-10 | 2010-03-09 | Novimmune S.A. | Neutralizing antibodies and methods of use thereof |
US7312320B2 (en) * | 2003-12-10 | 2007-12-25 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
DE602005021694D1 (de) * | 2004-12-10 | 2010-07-15 | Novimmune Sa | Kombinationstherapien gegen multiple toll-like-rezeptoren und ihre verwendung |
SI2173381T1 (sl) * | 2007-05-14 | 2014-01-31 | Novimmune Sa | Fc receptor-vezavni polipeptidi z modificiranimi efektorskimi funkcijami |
WO2009138494A2 (en) | 2008-05-15 | 2009-11-19 | Ablynx N.V. | Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors |
JP2012508012A (ja) * | 2008-11-04 | 2012-04-05 | イデラ ファーマシューティカルズ インコーポレイテッド | アンチセンスオリゴヌクレオチドによるToll様受容体4発現の調節 |
WO2012020038A1 (en) * | 2010-08-13 | 2012-02-16 | Roche Glycart Ag | Anti-tenascin-c a2 antibodies and methods of use |
WO2012096917A1 (en) * | 2011-01-10 | 2012-07-19 | Novimmune S.A. | Anti-tlr4 antibodies and methods of use thereof |
HUE037613T2 (hu) | 2012-03-29 | 2018-09-28 | Novimmune Sa | Anti-TLR4 antitestek és azok felhasználása |
JP2016539925A (ja) * | 2013-10-22 | 2016-12-22 | ノビミューン エスアー | Tlr4リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
AU2014359077A1 (en) * | 2013-12-06 | 2016-07-21 | Novimmune S.A. | Anti-TLR4 antibodies and methods of use thereof |
-
2013
- 2013-03-29 HU HUE13715871A patent/HUE037613T2/hu unknown
- 2013-03-29 WO PCT/US2013/034543 patent/WO2013149111A2/en active Application Filing
- 2013-03-29 DK DK13715871.3T patent/DK2831117T3/en active
- 2013-03-29 US US13/853,158 patent/US9453076B2/en active Active
- 2013-03-29 PL PL13715871T patent/PL2831117T3/pl unknown
- 2013-03-29 ES ES13715871.3T patent/ES2651692T3/es active Active
- 2013-03-29 AU AU2013237929A patent/AU2013237929B2/en active Active
- 2013-03-29 CN CN201710750112.2A patent/CN107868128A/zh active Pending
- 2013-03-29 JP JP2015503630A patent/JP6419064B2/ja active Active
- 2013-03-29 CA CA2869048A patent/CA2869048C/en active Active
- 2013-03-29 CN CN201380027744.6A patent/CN104540851B/zh active Active
- 2013-03-29 EP EP13715871.3A patent/EP2831117B1/en active Active
-
2016
- 2016-09-26 US US15/276,202 patent/US10400044B2/en active Active
-
2018
- 2018-10-09 JP JP2018190726A patent/JP2019038816A/ja active Pending
-
2019
- 2019-07-19 US US16/517,016 patent/US10982004B2/en active Active
-
2021
- 2021-11-15 US US17/526,883 patent/US20220324994A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US10982004B2 (en) | 2021-04-20 |
JP6419064B2 (ja) | 2018-11-07 |
CN104540851A (zh) | 2015-04-22 |
EP2831117B1 (en) | 2017-11-01 |
CN104540851B (zh) | 2017-09-15 |
US20220324994A1 (en) | 2022-10-13 |
AU2013237929A1 (en) | 2014-11-06 |
US10400044B2 (en) | 2019-09-03 |
US20130315914A1 (en) | 2013-11-28 |
EP2831117A2 (en) | 2015-02-04 |
US9453076B2 (en) | 2016-09-27 |
CA2869048C (en) | 2023-10-17 |
JP2019038816A (ja) | 2019-03-14 |
ES2651692T3 (es) | 2018-01-29 |
US20200207866A1 (en) | 2020-07-02 |
CN107868128A (zh) | 2018-04-03 |
AU2013237929B2 (en) | 2017-09-14 |
HUE037613T2 (hu) | 2018-09-28 |
CA2869048A1 (en) | 2013-10-03 |
WO2013149111A3 (en) | 2014-01-30 |
JP2015514094A (ja) | 2015-05-18 |
WO2013149111A2 (en) | 2013-10-03 |
DK2831117T3 (en) | 2017-12-18 |
US20170008967A1 (en) | 2017-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1207092A1 (en) | Anti-hla-b27 antibodies and uses thereof -hla-b27 | |
HRP20190358T1 (hr) | Antitijela protiv asic1 i njihova primjena | |
HK1211302A1 (en) | Asgpr antibodies and uses thereof asgpr | |
IL238559A0 (en) | Antibodies against ceacam5 and their use | |
ZA201407927B (en) | Anti-egfr antibodies and uses thereof | |
HK1200853A1 (en) | Meditopes and meditope-binding antibodies and uses thereof | |
HUE037613T2 (hu) | Anti-TLR4 antitestek és azok felhasználása | |
HK1205523A1 (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof ---1(big-et-1) | |
EP2830660A4 (en) | ANTI-SEMA4D ANTIBODIES AND EPITOPES | |
GB201208372D0 (en) | Antibodies and uses thereof | |
GB201209584D0 (en) | Modified antibodies |